Drug updated on 10/21/2024
| Dosage Form | Tablet (oral; 50 mg, 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor
- Indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial(s). [1]
- Pirtobrutinib has shown promising efficacy in patients with poor prognosis B-cell malignancies, including those previously treated with covalent BTK (Bruton Tyrosine Kinase) inhibitors. However, the abstract does not provide specific outcomes like response rates or survival metrics.
- The study aims to evaluate whether pirtobrutinib is superior to the investigator’s choice of covalent BTK inhibitors in patients with previously treated, BTK inhibitor-naive mantle cell lymphoma. Comparative effectiveness results from this phase III study are not provided in the abstract.
- The abstract does not include specific details on the effectiveness outcomes for different population types or subgroups.
- Pirtobrutinib is reported to be well tolerated in patients with poor prognosis B-cell malignancies, though no specific safety outcomes, percentages, or adverse effects are detailed in the abstract.
- The abstract does not provide any comparative safety data or significant safety concerns specific to pirtobrutinib or comparisons with covalent BTK inhibitors.
- Pirtobrutinib has been studied in patients with poor prognosis B-cell malignancies following prior therapy, including those previously treated with covalent BTK inhibitors, and is being evaluated in patients with previously treated, BTK inhibitor-naive mantle cell lymphoma, but the abstract does not provide specific subgroup outcomes or population-specific effectiveness data.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jaypirca (pirtobrutinib) Prescribing Information. | 2024 | Eli Lilly and Company, Indianapolis, IN |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress) | Data not availableSubjects F: null% M: null% | 2022 | Future Oncology |
Sex Distribution:
Year:
2022
Source:Future Oncology